Literature DB >> 23954271

Domestic cat microsphere immunoassays: detection of antibodies during feline immunodeficiency virus infection.

Britta A Wood1, Scott Carver, Ryan M Troyer, John H Elder, Sue VandeWoude.   

Abstract

Microsphere immunoassays (MIAs) allow rapid and accurate evaluation of multiple analytes simultaneously within a biological sample. Here we describe the development and validation of domestic cat-specific MIAs for a) the quantification of total IgG and IgA levels in plasma, and b) the detection of IgG and IgA antibodies to feline immunodeficiency virus (FIV) capsid (CA) and surface (SU) proteins, and feline CD134 in plasma. These assays were used to examine the temporal antibody response of domestic cats infected with apathogenic and pathogenic FIVs, and domestic cats infected with parental and chimeric FIVs of varying pathogenicity. The results from these studies demonstrated that a) total IgG antibodies increase over time after infection; b) α-CA and α-SU IgG antibodies are detectable between 9 and 28 days post-infection and increase over time, and these antibodies combined represent a fraction (1.8 to 21.8%) of the total IgG increase due to infection; c) measurable α-CD134 IgG antibody levels vary among individuals and over time, and are not strongly correlated with viral load; d) circulating IgA antibodies, in general, do not increase during the early stage of infection; and e) total IgG, and α-CA and α-SU IgG antibody kinetics and levels vary with FIV viral strain/pathogenicity. The MIAs described here could be used to screen domestic cats for FIV infection, and to evaluate the FIV-specific or total antibody response elicited by various FIV strains/other diseases.
© 2013.

Entities:  

Keywords:  Antibody detection; Domestic cat; Feline immunodeficiency virus; Microsphere immunoassay; Multiplexing

Mesh:

Substances:

Year:  2013        PMID: 23954271      PMCID: PMC3823060          DOI: 10.1016/j.jim.2013.08.001

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  52 in total

1.  Simultaneous measurement of antibodies to three HIV-1 antigens in newborn dried blood-spot specimens using a multiplexed microsphere-based immunoassay.

Authors:  R Bellisario; R J Colinas; K A Pass
Journal:  Early Hum Dev       Date:  2001-08       Impact factor: 2.079

Review 2.  Multiplexed particle-based flow cytometric assays.

Authors:  D A Vignali
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

3.  Virulence differences between two field isolates of feline immunodeficiency virus (FIV-APetaluma and FIV-CPGammar) in young adult specific pathogen free cats.

Authors:  N C Pedersen; C M Leutenegger; J Woo; J Higgins
Journal:  Vet Immunol Immunopathol       Date:  2001-05-10       Impact factor: 2.046

4.  Age-related differences in parameters of feline immune status.

Authors:  D J Campbell; J M Rawlings; S Koelsch; J Wallace; J J Strain; B M Hannigan
Journal:  Vet Immunol Immunopathol       Date:  2004-07       Impact factor: 2.046

5.  Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens.

Authors:  Genevieve G Fouda; Rose F G Leke; Carole Long; Pierre Druilhe; Ainong Zhou; Diane Wallace Taylor; Armead H Johnson
Journal:  Clin Vaccine Immunol       Date:  2006-10-11

6.  Feline immunodeficiency virus Gag- and Env-specific immune responses after vaginal versus intravenous infection.

Authors:  M J Burkhard; C K Mathiason; T Bowdre; E A Hoover
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

7.  Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.

Authors:  R Pu; J Coleman; M Omori; M Arai; T Hohdatsu; C Huang; T Tanabe; J K Yamamoto
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

8.  Use of CD134 as a primary receptor by the feline immunodeficiency virus.

Authors:  Masayuki Shimojima; Takayuki Miyazawa; Yasuhiro Ikeda; Elizabeth L McMonagle; Hayley Haining; Hiroomi Akashi; Yasuhiro Takeuchi; Margaret J Hosie; Brian J Willett
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

9.  Detection of human anti-flavivirus antibodies with a west nile virus recombinant antigen microsphere immunoassay.

Authors:  Susan J Wong; Valerie L Demarest; Rebekah H Boyle; Tian Wang; Michel Ledizet; Kalipada Kar; Laura D Kramer; Erol Fikrig; Raymond A Koski
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

10.  Characterization of a highly pathogenic molecular clone of feline immunodeficiency virus clade C.

Authors:  Sohela de Rozières; Candace K Mathiason; Matthew R Rolston; Udayan Chatterji; Edward A Hoover; John H Elder
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more
  7 in total

1.  HIV and FIV glycoproteins increase cellular tau pathology via cGMP-dependent kinase II activation.

Authors:  Matheus F Sathler; Michael J Doolittle; James A Cockrell; India R Nadalin; Franz Hofmann; Sue VandeWoude; Seonil Kim
Journal:  J Cell Sci       Date:  2022-06-21       Impact factor: 5.235

2.  FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge.

Authors:  Craig Miller; Mauren Emanuelli; Elizabeth Fink; Esther Musselman; Ryan Mackie; Ryan Troyer; John Elder; Sue VandeWoude
Journal:  NPJ Vaccines       Date:  2018-04-30       Impact factor: 7.344

3.  Prior Puma Lentivirus Infection Modifies Early Immune Responses and Attenuates Feline Immunodeficiency Virus Infection in Cats.

Authors:  Wendy S Sprague; Ryan M Troyer; Xin Zheng; Britta A Wood; Martha Macmillian; Scott Carver; Susan VandeWoude
Journal:  Viruses       Date:  2018-04-20       Impact factor: 5.048

4.  Pathogenesis of oral FIV infection.

Authors:  Craig Miller; Karen Boegler; Scott Carver; Martha MacMillan; Helle Bielefeldt-Ohmann; Sue VandeWoude
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

5.  HIV induces synaptic hyperexcitation via cGMP-dependent protein kinase II activation in the FIV infection model.

Authors:  Keira Sztukowski; Kaila Nip; Paige N Ostwald; Matheus F Sathler; Julianna L Sun; Jiayi Shou; Emily T Jorgensen; Travis E Brown; John H Elder; Craig Miller; Franz Hofmann; Sue VandeWoude; Seonil Kim
Journal:  PLoS Biol       Date:  2018-07-27       Impact factor: 8.029

6.  Serum Samples from Co-Infected and Domestic Cat Field Isolates Nonspecifically Bind FIV and Other Antigens in Enzyme-Linked Immunosorbent Assays.

Authors:  Alex Moskaluk; Mary Nehring; Sue VandeWoude
Journal:  Pathogens       Date:  2021-05-28

7.  Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax® FIV).

Authors:  Mark Westman; Dennis Yang; Jennifer Green; Jacqueline Norris; Richard Malik; Yasmin A Parr; Mike McDonald; Margaret J Hosie; Sue VandeWoude; Craig Miller
Journal:  Viruses       Date:  2021-03-12       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.